Regado Biosciences to Present at the 16th Annual BIO CEO & Investor Conference
BASKING RIDGE, N.J., Feb. 4, 2014 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced that it will present at the 16th Annual BIO CEO & Investor Conference taking place Feb. 10-11, 2014, at the Waldorf Astoria in New York City.
David J. Mazzo, Ph.D., chief executive officer of Regado Biosciences, will provide a corporate update during his presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.
A live audio webcast of the presentation will be available under the investor relations section of Regado's website at www.regadobio.com. A replay of the presentation will be available for 90 days following the event.
Monday, Feb. 10, 2014
10 a.m. EST
Waldorf Astoria, New York City
ABOUT REGADO BIOSCIENCES
Regado Biosciences, Inc., is a biopharmaceutical company focused on the development of novel, first-in-class, actively controllable antithrombotic drug systems for acute and sub-acute cardiovascular indications. Regado is pioneering the development of two-component drug systems consisting of a therapeutic aptamer and its specific active control agent. The company's lead product candidate, REG1, is a two-component system consisting of pegnivacogin, an anticoagulant aptamer specifically targeting coagulation Factor IXa, and its complementary oligonucleotide active control agent, anivamersen. REG1 is currently being evaluated in the REGULATE-PCI trial, a world-wide Phase 3 study enrolling 13,200 patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI), a hospital-based procedure used to mechanically open or widen obstructed coronary arteries. Regado's actively controllable product candidates have the potential to improve patient outcomes, enhance the patient experience and reduce overall treatment costs. More information can be found at www.regadobio.com.
For more information on REGULATE-PCI, please visit:
Investor Relations Contacts:
Tricia Truehart or Chelsea Wheeler
SOURCE Regado Biosciences, Inc.
More by this Source
Regado Biosciences to Provide Year-End and Fourth Quarter 2013 Financial Results
Mar 06, 2014, 07:30 ET
Regado Biosciences to Present at the 26th Annual ROTH Conference
Mar 05, 2014, 07:30 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.